Prescription of allopurinol and febuxostat during follow-up
| % (n) allopurinol | % (n) febuxostat | Mean mg dose (range) allopurinol users | Mean mg dose (range) febuxostat users | Total prescription urate lowering therapy at follow-up | |
| Before Baseline | 14.7 (31/211) | 0 | 109 (100–500) | 14.7% | |
| Month 1 | 95.0 (192/202) | 3.5 (7/202) | 119 (100–600) | 51 (40–80) | 98.5% |
| Month 2 | 95.3 (184/193) | 4.7 (9/193) | 190 (50–700) | 49 (40–80) | 100.0% |
| Month 3 | 94.2 (178/189) | 5.8 (11/189) | 236 (50–700) | 54 (40–80) | 100.0% |
| Month 6 | 90.4 (169/187) | 8.6 (16/187) | 273 (100–800) | 52 (40–120) | 99.0% |
| Month 9 | 89.2 (149/167) | 9.6 (16/167) | 280 (100–900) | 50 (40–80) | 95.8% |
| Month 12 | 87.6 (163/186) | 12.4 (23/186) | 289 (100–900) | 59 (40–120) | 100.0% |